{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T08:52:21Z","timestamp":1762419141550,"version":"build-2065373602"},"reference-count":10,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Cl\u00ednica Espa\u00f1ola (English Edition)"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.rceng.2021.01.009","type":"journal-article","created":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T23:59:51Z","timestamp":1631318391000},"page":"536-539","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Discordance in treatment of chronic obstructive pulmonary disease following GesEPOC guideline vs. GOLD"],"prefix":"10.1016","volume":"221","author":[{"given":"J.M.","family":"Figueira Gon\u00e7alves","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Golpe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Esteban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Acosta-Sorensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Veiga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Guzm\u00e1n-Peralta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2020","series-title":"Global initiative for chronic obstructive lung disease [Internet]","key":"10.1016\/j.rceng.2021.01.009_bib0005"},{"key":"10.1016\/j.rceng.2021.01.009_bib0010","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.arbres.2017.03.018","article-title":"Spanish Guidelines for Management of Chronic Obstructive Pulmonary Disease (GesEPOC) 2017. Pharmacological treatment of stable phase","volume":"53","author":"Miravitlles","year":"2017","journal-title":"Arch Bronconeumol."},{"key":"10.1016\/j.rceng.2021.01.009_bib0015","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMoa063070","article-title":"Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease","volume":"356","author":"Calverley","year":"2007","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rceng.2021.01.009_bib0020","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","article-title":"Once-daily single-inhaler triple versus dual therapy in patients with COPD","volume":"378","author":"Lipson","year":"2018","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rceng.2021.01.009_bib0025","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2147\/COPD.S48492","article-title":"Comparative efficacy of inhaled corticosteroid and long-acting beta agonist combinations in preventing COPD exacerbations: a Bayesian network meta-analysis","volume":"9","author":"Oba","year":"2014","journal-title":"Int J Chron Obstruct Pulmon Dis."},{"key":"10.1016\/j.rceng.2021.01.009_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2020.01.004","article-title":"Effect of inhaled corticosteroids on exacerbation of asthma-COPD overlap according to different diagnostic criteria","volume":"8","author":"Jo","year":"2020","journal-title":"J Allergy Clin Immunol Pract."},{"key":"10.1016\/j.rceng.2021.01.009_bib0035","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12931-019-1268-7","article-title":"Blood eosinophil count, a marker of inhaled corticosteroid effectiveness in preventing COPD exacerbations in post-hoc RCT and observational studies: systematic review and meta-analysis","volume":"21","author":"Harries","year":"2020","journal-title":"Respir Res."},{"key":"10.1016\/j.rceng.2021.01.009_bib0040","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01586-2018","article-title":"Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis","volume":"52","author":"Cazzola","year":"2018","journal-title":"Eur Respir J."},{"key":"10.1016\/j.rceng.2021.01.009_bib0045","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2147\/COPD.S60362","article-title":"Clinical benefit of fixed-dose dual bronchodilation with glycopyrronium and indacaterol once daily in patients with chronic obstructive pulmonary disease: a systematic review","volume":"9","author":"Ulrik","year":"2014","journal-title":"Int J Chron Obstruct Pulmon Dis."},{"key":"10.1016\/j.rceng.2021.01.009_bib0050","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.2147\/COPD.S217710","article-title":"An evaluation of single and dual long-acting bronchodilator therapy as effective interventions in maintenance therapy-na\u00efve patients with COPD","volume":"14","author":"Singh","year":"2019","journal-title":"Int J Chron Obstruct Pulmon Dis."}],"container-title":["Revista Cl\u00ednica Espa\u00f1ola (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2254887421001284?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2254887421001284?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T08:48:33Z","timestamp":1762418913000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2254887421001284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":10,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S2254887421001284"],"URL":"https:\/\/doi.org\/10.1016\/j.rceng.2021.01.009","relation":{},"ISSN":["2254-8874"],"issn-type":[{"type":"print","value":"2254-8874"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discordance in treatment of chronic obstructive pulmonary disease following GesEPOC guideline vs. GOLD","name":"articletitle","label":"Article Title"},{"value":"Revista Cl\u00ednica Espa\u00f1ola (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rceng.2021.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.rce.2021.01.009","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Medicina Interna (SEMI). All rights reserved.","name":"copyright","label":"Copyright"}]}}